CN1401391A - Use of casein and polypeptide in Chinese herbal medicine/Chinese patent medicine - Google Patents
Use of casein and polypeptide in Chinese herbal medicine/Chinese patent medicine Download PDFInfo
- Publication number
- CN1401391A CN1401391A CN02114444A CN02114444A CN1401391A CN 1401391 A CN1401391 A CN 1401391A CN 02114444 A CN02114444 A CN 02114444A CN 02114444 A CN02114444 A CN 02114444A CN 1401391 A CN1401391 A CN 1401391A
- Authority
- CN
- China
- Prior art keywords
- polypeptide
- casein
- medicine
- group
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A novel application of casein and its compound polypeptide in Chinese medicine is disclosed, which is characterized by that they can be directly added to Chinese medicine.
Description
Technical field
The present invention relates to the application in Chinese herbal medicine/Chinese patent medicine of a kind of casein and polypeptide.
Background technology
Chinese herbal medicine has long history in China, and its magical original curative effect is well-known, but the slow property on its healing time also is very general.Because Chinese herbal medicine or Chinese patent medicine are made by compatibility, its targeting is poor, contain vegetable protein in most of Chinese herbal medicine or the Chinese patent medicine in addition, but do not contain for macromole polypeptide proteinoid, thereby its curative effect has limitation.
In recent years studies show that to have than better nutrition of a plurality of aminoacid and physiological function with the low peptide of several aminoacid be combined intos, wherein many polypeptide classes also have crude protein or form the unexistent new function of aminoacid.Thereby both at home and abroad the research of peptide class is deepened continuously from the eighties.Existing now numerous products are widely used in food processing, for example be used for fields such as beverage special such as special child-bearing milk powder, beverage, oral liquid, liquid food, athlete and food, treatment food, anaphylaxis special food, beauty care cosmetics, along with deepening constantly of research.New application is also constantly being expanded, especially at field of medicaments.MARUYAMAS etc. have obtained dodecapeptide, seven peptides, pentapeptide and six peptides from the protolysate of bovine casein, the physiological function of these peptides has confirmed that now hypertensive ACE is had obviously inhibitory action, promptly act on and produce hypertensive reason, therefore it can absorb for a long time for the normal person, play health care, nutrition dual function, extremely safe.1986,88 years, Georgi, Hosono etc. found casein under specific acid supplement effect, had the bioactive peptide of antimutagenic to exist in the casein hydrolysis, and these peptides will lose antimutagenic as continuing hydrolysis to amino acid levels.
At present abroad, the research of various peptides is continuing in-depth, and the research of casein phosphopeptides is the brightest and the clearest, and existing a large amount of, all types of health product listing.Active casein polypeptide has antianaphylaxis, resisting hypertension, antimutagenic, immunomodulating, and slow down aging, hormone secretion and cell proliferation strengthen phagocyte, and the protection epidermis cell prevents multiple efficacies such as melanin deposition.External casein compound (activity) polypeptide is at health product, medicine, beverage, baby milk goods, curry meal, confection, and it is special that fields such as nutrition enhancer, feed additive, family's non-staple food, food additive play a part with different effects.Practice has confirmed that it is as safe as a house, nonhazardous, and the advantages such as physiological function that it is unique demonstrate it and have powerful superiority.1998, Germany will be used for medicine behind the casein phosphopeptides purification, and lists in the German state-promulgated pharmacopoeia.In the U.S., contain the peptide medicine and got permission to be used for curing some disease, such as dwarfism, infertility, pubertas praecox etc.Also some peptide class may be used for treating cancer, antidepressant, control insomnia etc.Acquired immunity deficiency disease and senile dementia etc.
Of the present invention open
The objective of the invention is casein and polypeptide to be added in Chinese herbal medicine or the Chinese patent medicine in order to provide a kind of, play the guiding role in Chinese herbal medicine by peptide, lead active ingredient in the Chinese herbal medicine, direction is arranged, on purpose act on focus, can improve therapeutic effect effectively, shorten treatment time.
Purpose of the present invention can realize by following measure:
The application in Chinese herbal medicine/Chinese patent medicine of a kind of casein and polypeptide is that casein and/or polypeptide are added in Chinese herbal medicine/Chinese patent medicine.
In Chinese herbal medicine/Chinese patent medicine, add casein and/or the polypeptide of the 0.1-40% of its total amount.Described casein and polypeptide are selected from the commercially available prod.Described polypeptide is selected from least a in the poly-peptide of casein polypeptide, soy sugars, ovalbumin peptide, fish protein peptide, the corn gluten protein peptide.
The present invention has following advantage compared to existing technology:
The present invention adds casein and polypeptide in Chinese herbal medicine or Chinese patent medicine, make to add macromole polypeptide proteinoid on the vegetable protein basis of Chinese herbal medicine; Make polypeptide become the guiding material of Chinese herbal medicine, lead active ingredient in the Chinese herbal medicine, direction is arranged, on purpose act on focus, can improve therapeutic effect effectively, shorten treatment time.
Enforcement of the present invention
The present invention also will be described in further detail in conjunction with the embodiments:
Embodiment 1:
The casein polypeptide is added in the Chinese patent medicine ZHENQI FUZHENG CHONGJI.The material combination that adds the FUZHENG CHONGJI of composite casein polypeptide is: Radix Astragali 30g, Fructus Ligustri Lucidi 12g, Radix Rehmanniae 20g, Fructus Lycii 30g, Radix Codonopsis 30g, Radix Glycyrrhizae 15g, Radix Angelicae Sinensis 8g, Poria 10g, Radix Bupleuri 6g, Fructus Jujubae 20g, casein polypeptide 18g.
Present embodiment, through effect of aging model mouse immune and peroxidation test are confirmed: the casein polypeptide is added into the activity that can strengthen aging model mouse brain tissue SOD in the ZHENQI FUZHENG CHONGJI, the effect that reduces the content of lipid peroxide product.
The experimental technique of present embodiment is as follows:
1. material
1.1 material
1.1.1 animal Kunming kind white mice, male and female half and half, body weight 20.0 ± 1.0g is provided by Lanzhou Inst. of Biological Products, Ministry of Public Health.The animal quality certification number: the moving word of doctor 14-001 number.
1.1.2 standard testing box
Respectively by Science and Technology Development Center of Chinese People's Liberation Army General Hospital put exempt from institute, the north put exempt from institute, bio-engineering research is built up in Nanjing that the standard testing box is provided, and detect by the Nuclear Medicine Department of Affiliated Hospital No.1, Lanzhou Medical College and the Gansu college of traditional Chinese medicine.
2. method and result
2.1 influence to aging model mouse brain tissue SOD's activity and cerebral tissue MDA content
110 of mices, male and female half and half, body weight 20.0 ± 1.0g is divided into 11 groups at random, and 10 every group, 6 weeks of capacity normal saline such as normal saline group ig; At the subcutaneous injection 5%D-of nape portion galactose and the corresponding medicine of while ig, capacity physiological salt liquid 0.5ML/ days such as model group ig, the polypeptide group is by large, medium and small dosage group ig polypeptide 1.8g/kg and 1.2g/kg, 0.6g/kg respectively for surplus experiment mice; Compound life peptide I group is by large, medium and small dosage group ig polypeptide 1.8g/kg+ ZHENQI FUZHENG CHONGJI 1.95g/kg, polypeptide 1.2g/kg+ ZHENQI FUZHENG CHONGJI 1.3g/kg, polypeptide 0.6g/kg+ ZHENQI FUZHENG CHONGJI 0.65g/kg; Compound life peptide II group is by large, medium and small dosage group ig polypeptide 1.8g/kg+ Fructus Lycii 0.03g/kg, polypeptide 1.2g/kg+ Fructus Lycii 0.02g/kg, polypeptide 0.6g/kg+ Fructus Lycii 0.01g/kg, once a day, getting cerebral tissue six weekends respectively makes 10% tissue homogenate and detects respectively.The active detection application of radiation of peroxide dismutase immunization is all measured by the explanation of standard testing box, and the detection of mda content is all used 7220 spectrophotometers and measured by the explanation of standard testing box.
2.1.1 compound life peptide I group is to the influence of aging model mouse brain tissue SOD's activity and MDA content
Table 1: to the influence of aging model mouse brain tissue SOD's activity and MDA content (X ± S)
Number of animals SOD MIDA model group 10 27.994 ± 0.337 27.948 ± 0.967 normal saline groups 10 34.793 ± 1.762
*26.328 ± 1.222
*Polypeptide group (greatly) 10 28.658 ± 0.878 27.517 ± 0.891
(in) 10 28.893 ± 1.198 26.850 ± 0.835
*
(little) 10 31.233 ± 2.416
*26.707 ± 1.271
*
Annotate: compare with model group:
*P＜0.05
*P＜0.01
2.1.2 compound life peptide I group is to the influence of aging model mouse brain tissue SOD's activity and MDA content
Table 2: to the influence of aging model mouse brain tissue SOD's activity and MDA content (X ± S)
Number of animals SOD MDA model group 10 27.994 ± 0.337 27.948 ± 0.967 normal saline groups 10 34.793 ± 1.762
*26.328 ± 1.222
*Compound life peptide I group (greatly) 10 31.311 ± 2.753
*25.672 ± 1.039
*
(in) 10 36.340 ± 1.690
*24.896 ± 0.764
*
(little) 10 42.197 ± 1.075
*22.655 ± 1.636
*
Annotate: compare with model group:
*P＜0.01
2.1.3 compound life peptide II group is to the influence of aging model mouse brain tissue SOD's activity and MDA content
Table 3: to the influence of aging model mouse brain tissue SOD's activity and MDA content (X ± S)
Number of animals SOD MDA model group 10 27.994 ± 0.337 27.948 ± 0.967 normal saline groups 10 34.793 ± 1.762
*26.328 ± 1.222
*Compound life peptide II group (greatly) 10 29.650 ± 1.458
*26.931 ± 1.043
*
(in) 10 41.003 ± 2.809
*23.776 ± 0.866
*
(little) 10 44.334 ± 1.693
*22.759 ± 1.318
*
Annotate: compare with model group:
*P＜0.05
*P＜0.01
2.2 to the aging model effect of immunologic function
150 of mices, male and female half and half, 15 groups of experiment branches and administration are the same, get the equal radioimmunology of detection of serum detection interleukin II (IL-2), interleukin-6 (IL-6) content six weekends respectively and measure by the explanation of standard testing box.
2.2.1 the polypeptide group is to the influence of aging model mice serum IL-2 content
Table 4: to the influence of serum il-2 content of aging model mice content (X ± S)
Number of animals IL-2 model group 10 0.949 ± 0.068 normal saline group 10 1.211 ± 0.076
*Polypeptide group (greatly) 10 1.002 ± 0.076
(in) 10 1.002 ± 0.060
(little) 10 1.167 ± 0.116
*
Annotate: compare with model group:
*P＜0.05
*P＜0.01
2.2.2 compound life peptide I group is to the influence of aging model mice serum IL-2 content
Table 5: to the influence of serum il-2 content of aging model mice content (X ± S)
Number of animals IL-2 model group 10 0.949 ± 0.068 normal saline group 10 1.211 ± 0.076
*Compound life peptide I group (greatly) 10 1.190 ± 0.095
*
(in) 10 1.241 ± 0.068
*
(little) 10 1.330 ± 0.125
*
Annotate: compare with model group:
*P＜0.05
*P＜0.01
2.2.3 compound life peptide II group is to the influence of aging model mice serum IL-2 content
Table 6: to the influence of serum il-2 content of aging model mice content (X ± S)
Number of animals IL-2 model group 10 0.949 ± 0.068 normal saline group 10 1.211 ± 0.076
*Compound life peptide I group (greatly) 10 1.050 ± 0.082
*
(in) 10 1.174 ± 0.101
*
(little) 10 1.260 ± 0.086
*
Annotate: compare with model group:
*P＜0.05
*P＜0.01
3, discuss
Aging is a normal and complex physical phenomenon in the life process, is the combined process of various biochemical reactions in the body.With advancing age, free-radical generating increase and the related enzyme activity of removing free radical descends and body's immunity under the multiple factor of degradation all be that old and feeble important mechanism takes place body.Superoxide dismutase (SOD) but the disproportionation of Catalytic Oxygen free radical be the important enzyme that body is removed oxygen-derived free radicals, and body with advancing age, oxygen-derived free radicals produces to be increased, tissue SOD is active simultaneously reduces, and causes oxygen-derived free radicals to be piled up.Free radical is (as O
2,-OOH etc.) can pass through compositions such as peroxidation attack cells film, RNA and protein, cause lipid peroxidation and promote molecule crosslinked, DNA gene mutation and dna replication dna unusual; Promote the unsaturated fatty acid on the cell membrane to produce peroxidization, form malonaldehyde (MDA) etc., (Lipofascin LK) deposits in the enzyme body, causes cell function to be badly damaged, body thereby be tending towards old and feeble gradually can to form the macromole lipofuscin simultaneously.
After people in middle age, normal immunologic function is decline gradually along with age growth, and the immunologic function decline is one of reason of human senility.The main biological activity of IL-2 is to promote CTL and NK cell proliferation; Promote B cell differentiation and propagation, enhancing antibody generates, and induces to generate the activated killer cell of lymphokine.LI-2 and IL-2 receptor system are the media of T cell transformation and mixed lymphocyte reaction.The old people produces the IL-2 ability, and IL-2 expression of receptor ability and autologous mixed lymphocyte reaction ability reduce, and is the main cause that the T cell division capacity reduces.IL-2 has important function in immunne response, immunomodulating in antineoplastic immune, thereby IL-2 generation minimizing can be quickened the process of human senility.
Using Chinese medicine prevention malignant tumor and slow down aging also is the focus of Recent study, and makes significant progress.Traditional medicine is from integral viewpoint, says as " element is asked, vital QI of the body connecting with natural QI discuss ": " YIN and YANG in a relative equilibrium, life activities being normally maintained; Dissociation of YIN from YANG, exhaustion of vital essence ", point out that the old and feeble and dead basic reason of body is the six climate exopathogens exopathogen, the imbalance of YIN and YANG due to the deficient five internal organs or from determining, strengthening healthy qi, regulating yin and yang are the key of slow down aging.Malignant tumor belongs to categories such as the traditional Chinese medical science " cancer ", " rock ", " disliking swollen ", " gathering ", be deficiency of vital QI, the exopathogen of being detained, qi depression to blood stasis, evil poison gather, accumulate due to the strongly fragrant in bulk, its treatment rule has strengthening the body resistance method, dredge the meridian passage method, activating blood and removing stasis Method, hard masses softening and resolving method, depressed liver-energy dispersing and QI regulating method etc.As Fructus Lycii etc. is slow down aging, antineoplastic key medicine.
Modern pharmacological research is found: Fructus Lycii has the obvious suppression effect to the KATO-III cell, mainly shows as synthetic, the interference cell division growth of inhibition DNA; Ultrastructure shows cellular change, organelle are subjected to destruction in various degree.The lycium barbarum polysaccharide injection can significantly promote splenocyte propagation, and LAK cell anti-tumor activity raises, and external IL-2 consumption reduces 75%.Especially serve as obvious to improve quick LAK activity.The acetone extract of Fructus Lycii has the mutation inhibiting effect to the inductive mutant TA98 of carcinogen, TA100, and suppression ratio is respectively 91.8%, 82.6%.Illustrate that Fructus Lycii has antimutagen to resist, block mutagenic action with having.Fructus lycii extracted solution reaches the nucleus formation that in vivo test all has obvious inhibition Mouse Liver lipid peroxide (LPO) in vitro, and is dose-response relationship; And intravital mouse blood two-story valley peptide peroxidase (GSH-PX) vigor and erythrocyte superoxide dismutase (SOD) vigor are increased: human trial shows that can obviously suppress Serum LPO generates, and makes that the GSH-PX vigor increases in the blood.Oral in advance Fructus Lycii; can obviously reduce old people's SCE frequency that the mutagenic agent ametycin brings out; illustrate that Fructus Lycii can improve old people DNA repair ability, damage has protective effect to hereditary material, and the prompting fructus lycii extracted solution has delaying senility function.Kudzu vine root S86019 has obvious inhibitory action to people's acute promyelocytic leukemia cell strain HL-60 cell proliferation, is an effective HL-60 cell-differentiation inducers.Studies confirm that Radix Puerariae has and obviously induces tumor necrosis factor (TNF) effect.
Compound life peptide health care, the therapeutic effect of Chinese medicine and polypeptides matter combination development is better, be applied in people's health therapy, the trend that adapts to human medical treatment " going back to nature ", the society need of green natural medicine be can satisfy, the new health care of health developing a slice of human body, the treatment world are.
This experimentation has been observed the polypeptide group, compound life peptide I group (polypeptide+FUZHENG CHONGJI), compound life peptide II group (polypeptide+Fructus Lycii) is to the active influence of mouse aging cerebral tissue SOD due to the D-galactose, experimental result is found compound life peptide I group, compound life peptide II group, compound life peptide III group all has the activity of certain enhancing aging model mouse brain tissue SOD, reduce the effect of lipid peroxide product (MDA) content, and I, strong and the I group of II group, and be proportionate with dosage, show that said preparation has the anti-peroxidation effect, this effect may be one of anti-aging effects mechanism of said preparation.
In addition, polypeptide I group, compound life peptide I group, compound life peptide II group are spared the effect that can increase aging model mice serum interleukin II (IL-2) content, and the strong and polypeptide group of I, II group, and are proportionate with dosage.
In sum, compound life peptide can strengthen aging model mouse anti peroxidation and immunologic function, thereby can bring into play delaying senility course.
Embodiment two:
Casein is added in traditional Chinese patent medicine XIANGSHA YANGWEI WAN.Its compatibility is: Radix Codonopsis 20g, Rhizoma Atractylodis Macrocephalae 10g, Poria 8g, Rhizoma Atractylodis 5g, Radix Glycyrrhizae 5g, Pinellia leaven 6g, Pericarpium Citri Reticulatae 5g, Fructus Amomi 25g, Radix Aucklandiae 20g, Rhizoma Cyperi 10g, Fructus Aurantii 10g, Cortex Magnoliae Officinalis 15g, Massa Medicata Fermentata 10g, Fructus Crataegi cuneatae 20g, Fructus Hordei Germinatus 15g, Semen Raphani 10g, casein 36g.
Embodiment three:
The poly-peptide of soy sugars is added in traditional Chinese patent medicine Cinnabar Sedative Pill.Its compatibility is: Cinnabaris 200g, Rhizoma Coptidis 300g, Radix Rehmanniae 200g, Radix Angelicae Sinensis 200g, Radix Glycyrrhizae 200g, the poly-peptide 44g of soy sugars.
Embodiment four:
Ovalbumin peptide is added in traditional Chinese patent medicine detoxicating tablet of cow-bezoar.Its compatibility is: Calculus Bovis 5g, Radix Et Rhizoma Rhei 200g, Radix Scutellariae 150g, Gypsum Fibrosum 200g, Radix Platycodonis 100g, Realgar 50g, Borneolum Syntheticum 25g, Radix Glycyrrhizae 50g, ovalbumin peptide 200g.
Claims (3)
1, a kind of casein and the polypeptide application in Chinese herbal medicine/Chinese patent medicine; It is characterized in that casein and/or polypeptide are added in Chinese herbal medicine/Chinese patent medicine.
2, casein as claimed in claim 1 and the polypeptide application in Chinese herbal medicine/Chinese patent medicine is characterized in that in Chinese herbal medicine/Chinese patent medicine adding casein and/or the polypeptide of the 0.1-40% of its total amount.
3, casein as claimed in claim 1 and the polypeptide application in Chinese herbal medicine/Chinese patent medicine is characterized in that described polypeptide is selected from least a in the poly-peptide of casein peptide, soy sugars, ovalbumin peptide, fish protein peptide, the corn gluten protein peptide.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN021144443A CN1401391B (en) | 2002-02-05 | 2002-02-05 | Use of casein and polypeptide in Chinese herbal medicine/Chinese patent medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN021144443A CN1401391B (en) | 2002-02-05 | 2002-02-05 | Use of casein and polypeptide in Chinese herbal medicine/Chinese patent medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1401391A true CN1401391A (en) | 2003-03-12 |
| CN1401391B CN1401391B (en) | 2010-09-01 |
Family
ID=4743101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN021144443A Expired - Fee Related CN1401391B (en) | 2002-02-05 | 2002-02-05 | Use of casein and polypeptide in Chinese herbal medicine/Chinese patent medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1401391B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104305214A (en) * | 2014-10-13 | 2015-01-28 | 山东省海洋生物研究院 | Food capable of improving immunity and preparation method thereof |
-
2002
- 2002-02-05 CN CN021144443A patent/CN1401391B/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104305214A (en) * | 2014-10-13 | 2015-01-28 | 山东省海洋生物研究院 | Food capable of improving immunity and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1401391B (en) | 2010-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101066445A (en) | Chinese medicine prepn for curing gastropathy radically | |
| CN1314422C (en) | Shiweifuzheng medicine for tonifying qi and blood, warning yang and strengthening spleen and its prepn process | |
| CN1255181C (en) | Preparation of medicinal composition for nourishing | |
| CN101053621A (en) | Traditional Chinese medicinal composition for treating obesity and its preparation method | |
| CN105617354A (en) | Medicine for treating rheumatism and rheumatoid | |
| CN101716256A (en) | Preparation used for strengthening immunity and inhibiting tumor | |
| CN1256133C (en) | Antifatigue Chinese medicine composition and its prepn process | |
| CN101711848A (en) | Chinese medicinal composition capable of adjunctively treating tumour | |
| CN114748603B (en) | Pharmaceutical composition for preventing and treating new coronavirus pneumonia from changing or restoring yang and application thereof | |
| CN1232298C (en) | Medication for treating malignant tumor and preparation method | |
| CN110934924A (en) | Traditional Chinese medicine bone marrow hematogenesis composition and application thereof | |
| CN1060657C (en) | Nourishing medicine for preventing and curing toxic and side effect after tumor radiotherapy and chemotherapy and preparation method | |
| CN1401391B (en) | Use of casein and polypeptide in Chinese herbal medicine/Chinese patent medicine | |
| CN101199749A (en) | Chinese medicine for treating AIDS | |
| CN1130515A (en) | Chinese drug for treating chronic colitis | |
| CN111558016A (en) | Traditional Chinese medicine composition with effects of protecting teeth and strengthening bones and traditional Chinese medicine preparation | |
| CN1158091C (en) | Chinese medicine composition for treating lung cancer | |
| CN1140071A (en) | Anticancer drug and preparing method thereof | |
| CN1101560A (en) | Medicine for curing encephalatrophy | |
| CN104524233A (en) | Biological reaction regulator capable of promoting hematopoietic function and enhancing immunity, preparation and application thereof | |
| CN103610991B (en) | Medicine being used for the treatment of swine gastric ulcer and preparation method thereof | |
| CN1611249A (en) | Antisenescent longevity powder | |
| CN1256976C (en) | Anti-cancer Chinese medicinal composition and its preparing method | |
| CN1121237C (en) | Health-care products for regulating immunological function and delaying senility | |
| CN1150015C (en) | Medicine for treating leucocytopenia caused by lupus erythematosus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100901 Termination date: 20120205 |